• Separating Growth Arrest from Cancer Cell Killing

  2026-09-28

  Hannah Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central finding—that drugs can affect proliferation and cell death in different proportions and on different timelines—supports using response measures that distinguish these processes when interpreting in vitro experiments.

• GSK343 Workflow for EZH2 and H3K27me3 Studies

  2026-09-27

  Use GSK343 to test whether EZH2-dependent H3K27me3 helps maintain gene repression, then connect chromatin changes to transcription and cell phenotype. This workflow emphasizes dose-aware controls and a cautious extension from cancer models to TERT regulation in human pluripotent stem cells.

• Large-Scale Gastruloid Arrays Reveal Aneuploid Phenotypes

  2026-09-26

  The study introduces an indexed microraft array that supports imaging and automated sorting of individual human gastruloids at a scale suited to comparative assays. Applying the platform to euploid and aneuploid gastruloids revealed differences in DNA per area and expression of spatial-patterning genes, while also showing substantial variation among gastruloids in the same group.

• Anlotinib in Intra-Abdominal DSRCT

  2026-09-26

  This case report describes shrinkage of metastatic lymph nodes after anlotinib treatment in a 38-year-old man with intra-abdominal desmoplastic small round cell tumor (IADSRCT), followed by maintenance treatment. It offers an early clinical signal for a multi-target tyrosine kinase inhibitor in a rare cancer, but the single-patient design cannot establish efficacy or define a treatment standard.

• Sorafenib Workflows for Liver Cancer Research

  2026-09-25

  Build reproducible Sorafenib experiments around matched dose–response, pathway, and angiogenesis readouts—not viability alone. This guide connects BAY-43-9006 workflows to emerging mitochondrial cholesterol and mitophagy research while keeping those mechanisms experimentally distinct.

• Milk Vesicle Uptake in Porcine Intestinal Stem Cell Models

  2026-09-25

  This study establishes three porcine intestinal stem cell model formats to examine milk-derived extracellular vesicles in a physiologically organized epithelium. Its key findings link vesicle uptake to apical accessibility and show that milk vesicles influence stemness- and differentiation-associated gene expression in colon-derived models, while inhibitor experiments indicate an endocytosis-sensitive uptake process.

• Pazopanib Hydrochloride: Arrest or Cell Death?

  2026-09-24

  Pazopanib Hydrochloride (GW786034) is a multi-target kinase inhibitor whose effects can look different depending on how an experiment measures response. This guide connects its anti-angiogenic mechanism to a practical framework for separating growth inhibition from cell killing in cancer research.

• Anlotinib’s Preclinical VEGFR2 Profile

  2026-09-24

  The 2018 study characterized anlotinib as a potent, selective VEGFR2 inhibitor and connected kinase inhibition to endothelial-cell responses, vessel growth, and tumor-model outcomes. Its combination of biochemical, cellular, explant, and in vivo experiments provides a useful framework for evaluating anti-angiogenic activity while highlighting the limits of extrapolating preclinical results.

• Nintedanib (BIBF 1120) in Glioma Research

  2026-09-23

  Nintedanib (BIBF 1120) gives researchers a practical way to interrogate VEGFR, FGFR, and PDGFR dependence across cancer and fibrosis models. This workflow translates ATRX-stratified glioma findings into controlled dosing, combination, apoptosis, and angiogenesis assays while emphasizing solubility, exposure, and interpretation safeguards.

• From Glycan Mechanisms to PCR-Ready Translation

  2026-09-22

  Mechanistic oncology is increasingly revealing how genotype-driven metabolism reshapes tumor biology. This thought-leadership guide connects the GMDS–core fucosylation findings in MYCN-amplified neuroblastoma with practical DNA amplification, genotyping, cloning, and translational workflow strategy using the 2X Taq PCR Master Mix (with dye).

• Anlotinib and VEGFR2–PDGFRβ–FGFR1 Angiogenesis

  2026-09-22

  The reference study shows that anlotinib suppresses angiogenesis by jointly inhibiting VEGFR2, PDGFRβ, and FGFR1 signaling rather than acting through a single angiogenic axis. Its combination of endothelial-cell assays, ex vivo vessel sprouting models, and mechanistic signaling analysis provides a useful framework for cancer research workflows focused on angiogenesis.

• Anlotinib and VEGFR2-Driven Tumor Angiogenesis

  2026-09-21

  The reference study established anlotinib as a highly potent, orally active VEGFR2 inhibitor whose antitumor activity is driven primarily by suppression of tumor-associated angiogenesis. Its integrated biochemical, endothelial, ex vivo vessel, and xenograft experiments show why vascular selectivity can produce strong efficacy while limiting reliance on direct tumor-cell cytotoxicity.

• Z-DEVD-FMK in Mechanistic Apoptosis Assays

  2026-09-21

  Z-DEVD-FMK is a cell-permeable caspase-3 inhibitor that can turn apoptosis assays into mechanistic experiments. This article uses graphene-induced melanoma apoptosis to show how paired pathway readouts, calpain awareness, and rigorous controls improve interpretation.

• Anlotinib in Desmoplastic Small Round Cell Tumor

  2026-09-20

  A 2019 case report described disease control with anlotinib in metastatic intra-abdominal desmoplastic small round cell tumor after surgery and chemotherapy. The report is notable as an early clinical signal for applying a multi-target tyrosine kinase inhibitor to a rare, aggressive sarcoma, while its single-patient design limits conclusions about efficacy and survival.

• LINC02870 Drives SNAIL Translation in Liver Cancer

  2026-09-19

  The reference study identifies LINC02870 as a potentially oncogenic long non-coding RNA that is enriched in hepatocellular carcinoma, particularly HBV-positive disease. Its central mechanistic contribution is linking LINC02870 to EIF4G1-dependent enhancement of SNAIL translation, providing a molecular explanation for increased HCC growth, migration, invasion, and poor prognosis.

8467 records 1/565 page Next 12345 下5页 Last page